INCR News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

IN

Volume

5.11K

Loading chart

IN

INCRIntercure Ltd. Ordinary Shares

INCR

Pay with—

Available Balance0.00

IN

Mkt Cap

$69.8M

Volume

5.11K

Next Earnings

N/A

Chart Financials Earnings News About Insider Filings

InterCure Secures NIS 22 Million in Private Placement Financing Led by Leading Pharma-Focused Hedge FundsInterCure Ltd. announced a binding term sheet for NIS 22 million (approximately US$7.4 million) in private placement financing, with potential to increase to NIS 54 million. The funding includes investments from CEO Alexander Rabinovich and leading pharma-focused hedge funds including Bennu Pharma Fund Ltd. The company plans to use proceeds for global expansion, particularly in Germany and U.S. regulated medical cannabis markets, as well as recovery and expansion of its Nir Oz facility.GlobeNewswire Inc. · Jun 22, 2026

InterCure Receives Nasdaq Notification Regarding Minimum Bid RequirementInterCure Ltd. (Nasdaq: INCR) received a notice from Nasdaq on February 25, 2026, indicating non-compliance with the minimum bid price requirement of $1.00 per share. The company has been granted a 180-calendar day compliance period until August 24, 2026, to regain compliance. InterCure plans to consider a reverse share split as part of its strategy to meet the requirement. The company's shares will continue trading on Nasdaq during this period.GlobeNewswire Inc. · Mar 3, 2026

InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash of NIS 43 MillionInterCure reported preliminary 2025 revenue of NIS 265 million, representing 11% growth year-over-year with nearly 20% growth in H2 2025. The company achieved its twelfth consecutive half-year of positive Adjusted EBITDA and generated first significant revenues from the German market. The company also announced strategic acquisitions of Botanico Ltd. and a 28% stake in Cannasoul R&D Ltd., along with NIS 81 million in war-related compensation advances from Israeli authorities.GlobeNewswire Inc. · Feb 19, 2026

InterCure Enters Premium US Cannabis Market With ISHI DealInterCure Ltd. announced its acquisition of Botanico Ltd. (ISHI), gaining access to advanced AI-driven cultivation technologies and exclusive US cannabis brand partnerships, positioning itself for potential industry expansion amid potential cannabis rescheduling.Benzinga · Sep 19, 2025

InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 millionInterCure reported revenue of NIS 126 million and adjusted EBITDA of NIS 21 million for the first half of 2024. The company's southern facility was affected by a terrorist attack and the war in Gaza, but it is entitled to compensation from the Israeli authorities. InterCure plans to expand its partnership with Cookies and launch products in Germany and the UK.GlobeNewswire Inc. · Aug 29, 2024

Asset-Light Expansion Into $8B German Market Adds Potential To This Cannabis Stock On NASDAQThe potential rescheduling of cannabis in the U.S. and the growing demand in Germany positions InterCure (NASDAQ: INCR), the leading seller of pharmaceutical cannabis outside North America, to capitalize on these opportunities, according to a recent initiation note by Pablo Zuanic of Zuanic & Associates. Zuanic highlighted said that "InterCure's experience in Israel, a market five years ahead of Germany in development, gives it a competitive edge." He also noted that "down the road, INCR could enter the U.S. market if FDA-approved and controlled pharmaceutical cannabis is federally legalized. In a global industry context, InterCure has strategic value." Market Position And Growth Potential InterCure has a significant presence in Israel, accounting for 98% of its sales, and is poised for substantial growth due to recent regulatory changes, expected to result in a 2-3x increase in demand. The company's expertise in pharmaceutical cannabis positions it as a strategic player in the global market. "InterCure has strategic value with its ability to produce quality flowers at scale under strict GMP standards," Zuanic wrote. Financial Performance Despite disruptions caused by the Oct 7 attacks, which led to a 50% drop in 4Q23 sales, InterCure is expected to rebound with double-digit sequential growth throughout 2024. The company's southern facility, which was damaged during the attacks, is anticipated to resume production by late 3Q24 or early 4Q24. Zuanic projects the company ...Full story available on Benzinga.comBenzinga · May 24, 2024

InterCure Provides an Update Regarding Nir Oz FacilityNEW YORK, and HERZLIYA, Israel, Feb. 13, 2024 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical cannabis company in Israel and outside of North America, reports today that, further to the Company’s press release issued on October 17, 2023, in which the Company provided an update regarding the status of the security situation in Israel, and its impact on the Company and its employees, the Company is providing an additional update regarding the status of its facility in Kibbutz Nir Oz (the “Southern Israel Site”).GlobeNewswire Inc. · Feb 13, 2024

InterCure Signs Definitive Agreement to Acquire Leon Cannabis Pharmacy ChainNEW YORK, and HERZLIYA, Israel, Jan. 31, 2024 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical cannabis company in Israel and outside of North America, announced today that it has entered into a share purchase agreement (the “Agreement”) with the shareholders of Leon Pharm Ltd. (the “Sellers”, and “Leon Pharm”, respectively) to purchase Leon Pharm, a leading, Israel-based pharmacy chain specializing in dispensing medical cannabis in Israel, by way of a share purchase of all of the issued and outstanding share capital of Leon Pharm (the “Transaction”).GlobeNewswire Inc. · Jan 31, 2024

InterCure Wins Cannolam Arbitration ProceedingNEW YORK and HERZLIYA, Israel , Oct. 31, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical cannabis company in Israel and outside of North America, reports today that, further to the Company’s press release issued on August 31, 2023, in which the Company reported that the Tel Aviv-Jaffa District Court dismissed the lawsuit that filed against the Company by minority shareholders of its subsidiary, Cannolam Ltd. (“Cannolam”), and the parties agreed on a binding arbitration process (the “Arbitration”), in which the amount owed to the Company and the parties will be determined and paid as part of a full separation process, the Company hereby reports that the Arbitration has been concluded, and the arbitrator has decided in favor of the Company on most of the claims presented to him by the Company, while rejecting almost all of the claims presented by the minority shareholders.GlobeNewswire Inc. · Oct 31, 2023

InterCure Provides an Update Regarding the Security Situation in IsraelNEW YORK, and HERZLIYA, Israel, Oct. 17, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical cannabis company in Israel and outside of North America, today addressed the status of the security situation in the State of Israel, and its impact on the Company and its employees.GlobeNewswire Inc. · Oct 17, 2023

to start trading

IN

INCRIntercure Ltd. Ordinary Shares

INCR

Pay with—

Available Balance0.00

Your PositionYou don't own any INCR yet.

Related Tickers

Earnings